Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Mayne Pharma Launches Budesonide Capsules in the US | Contract Pharma

What are you searching for?

Sign in
Breaking News

Mayne Pharma Launches Budesonide Capsules in the US

A generic alternative to Entocort EC

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Mayne Pharma has launched budesonide capsules in a 3 mg dose in the U.S. Budesonide is a generic alternative to Entocort EC, which is used as a treatment for patients with mild to moderate Crohn’s disease. 

“This latest addition to Mayne Pharma’s fast-growing generic portfolio reflects the company’s core strengths in complex drug delivery formulations and technologies,” said Stefan Cross, president, Mayne Pharma USA. “This expertise paves the way to creating more high-quality generic alternatives that ultimately provide patients with greater choices, better access and more affordable solutions for their improved health.”

According to IMS Health, branded and generic sales of budesonide in the U.S. were approximately $322 million for the 12 months ending Aug. 31.

Mayne Pharma markets more than 50 products and has a growing pipeline of more than 40 generic and branded drug products for the U.S. market representing IMS Health sales greater than $7 billion. Currently, Mayne Pharma has 19 product applications pending at the U.S. Food and Drug Administration.    

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics